Selecky Christobel: insider trades.
Selecky Christobel reported 10 non-derivative transactions on 2 SEC ownership filings in Q3 2026: 0 open-market purchases and 3 sales ($2.3M), across 1 company.
- Transactions
- 10
- Purchases (P)
- 0
- Sales (S)
- 3
- Companies
- 1
- Name as filed
- Selecky Christobel
Companies
| Company | Relationship | Transactions |
|---|---|---|
| ImmunityBio, Inc. (IBRX) | Director | 10 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-07-01 | ImmunityBio, Inc. | M | 35,064 | $2.98 | 35,064 | Form 4 |
| 2026-07-01 | ImmunityBio, Inc. | S | 159,478 | $9.02 | 0 | Form 4 |
| 2026-07-01 | ImmunityBio, Inc. | M | 124,414 | $2.99 | 159,478 | Form 4 |
| 2026-06-30 | ImmunityBio, Inc. | S | 1,000 | $9 | 0 | Form 4 |
| 2026-06-30 | ImmunityBio, Inc. | M | 300 | $2.99 | 1,000 | Form 4 |
| 2026-06-30 | ImmunityBio, Inc. | M | 700 | $2.98 | 700 | Form 4 |
| 2026-06-29 | ImmunityBio, Inc. | M | 32,173 | $2.98 | 32,173 | Form 4 |
| 2026-06-29 | ImmunityBio, Inc. | M | 33,549 | $2.99 | 65,722 | Form 4 |
| 2026-06-29 | ImmunityBio, Inc. | M | 30,000 | $2.84 | 95,722 | Form 4 |
| 2026-06-29 | ImmunityBio, Inc. | S | 95,722 | $9.01 | 0 | Form 4 |
Questions
What stock did Selecky Christobel buy or sell?
Selecky Christobel reported 10 non-derivative transactions on 2 SEC ownership filings in Q3 2026: 0 open-market purchases and 3 sales ($2.3M), across 1 company.
Is Selecky Christobel the same person as other filers with this name?
This page covers SEC CIK 1849739 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/selecky-christobel-1849739.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.